Dried Blood Spot Collection Cards Market Size & Share Analysis - Growth Trends And Forecast (2024 - 2031)
By Application Type;
New Born Screening (NBS), Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, CRO/Research and OthersBy Card Type;
Whatman 903, Ahlstrom 226, FTA and OthersBy End Use;
Hospitals & Clinics, Diagnostics Centers and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Dried Blood Spot Collection Cards Market Overview
Dried Blood Spot Collection Cards Market (USD Million)
Dried Blood Spot Collection Cards Market was valued at USD 310.21 million in the year 2024. The size of this market is expected to increase to USD 413.19 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.2%.
Dried Blood Spot Collection Cards Market
*Market size in USD million
CAGR 4.2 %
| Study Period | 2026 - 2032 |
|---|---|
| Base Year | 2025 |
| CAGR (%) | 4.2 % |
| Market Size (2025) | USD 310.21 Million |
| Market Size (2032) | USD 413.19 Million |
| Market Concentration | High |
| Report Pages | 366 |
Major Players
- F. Hoffmann-La Roche Ltd
- QIAGEN
- Shimadzu Scientific Instruments
- Eastern Business Forms, Inc
- Ahlstrom-Munksjö
- PerkinElmer
- ARCHIMEDlife
- CENTOGENE N.V
- Hemaxis
- Lipomic Healthcare
- Gentegra LLC
- Thomas Scientific
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Dried Blood Spot Collection Cards Market
Fragmented - Highly competitive market without dominant players
Dried Blood Spot Collection Cards Market is expanding rapidly as these cards become essential in diagnostic programs, especially for early disease screening. More than 60% of newborn health screenings now rely on DBS cards, showcasing their critical role in healthcare. Their affordability and ease of use support widespread adoption in routine testing environments.
Advantages Driving Demand
DBS cards offer simple, stable, and low-volume blood collection solutions, making them ideal for various clinical and laboratory uses. Currently, about 45% of labs apply DBS cards in biomarker research and infectious disease analysis. Their ambient storage capability reduces logistical challenges and boosts efficiency in resource-limited settings.
Utility in Drug Trials and Research
DBS cards are increasingly utilized in clinical research and pharmaceutical trials, especially for blood sample collection in early drug development. Nearly 50% of bioanalytical processes use DBS methods to ensure better patient compliance and reduce operational strain. This trend is helping pharmaceutical companies improve trial efficiency.
Technological Advancements Supporting Growth
Innovations in automated processing and integration technologies are enhancing the functionality of DBS cards. Roughly 40% of clinical labs have adopted automation-ready DBS systems to optimize their workflows. These advances are helping expand the market’s reach across diagnostics, research labs, and healthcare settings.
Dried Blood Spot Collection Cards Market Key Takeaways
-
The global market for dried blood spot (DBS) collection cards is expanding steadily, with significant growth expected over the coming years, reflecting a consistent upward trajectory.
-
The growing use of DBS cards for newborn screening, infectious disease testing, therapeutic drug monitoring, forensic analysis and drug‑residue/toxicology testing is driving broad adoption across clinical, research and diagnostic settings.
-
The market is receiving a boost from increasing demand in developing regions especially in Asia‑Pacific due to rising awareness, expanding healthcare access and need for cost‑effective diagnostics.
-
Major established players such as manufacturers of filter‑paper and polymer‑based DBS cards are expanding portfolios and leveraging their global footprint to meet rising demand, thereby strengthening competitive intensity worldwide.
-
The relatively low cost, ease of sample collection, storage and transport, and suitability for remote or resource‑limited settings make DBS cards a preferred alternative to conventional venous blood tests in many applications.
-
The market outlook remains favorable as ongoing advances in diagnostic technologies, rising emphasis on public health screening programs, and expansion of therapeutic drug monitoring and forensics applications continue to fuel demand.
-
Regions such as North America currently hold a substantial share due to advanced healthcare infrastructure and high adoption rates, while Asia‑Pacific is expected to register the fastest growth over the forecast period.
Dried Blood Spot Collection Cards Market Recent Developments
-
In August 2022, Boston Heart Diagnostics Corporation launched a broad range of tests with a dried blood spot collection for a broad range of applications including cardiovascular risk factors, type 2 diabetes, and wellness assessments for cognitive, nutritional, women's, and men's health.
-
In June 2022, a group of researchers from the Division of Vector-Borne Diseases, Fort Collins, conducted a study to assess the use of Whatman FTA cards in molecular diagnostics for the detection of Yellow Fever Virus (YFV). The study showed that the card can be easy to use and cost-effective in the molecular diagnosis of yellow fever. Furthermore, it allows the physician to preserve viral RNA without a cold chain.
Dried Blood Spot Collection Cards Market Segment Analysis
In this report, Dried Blood Spot Collection Cards Market has been segmented by Application Type, Card Type, End Use and Geography.
Dried Blood Spot Collection Cards Market, Segmentation by Application Type
The Application Type segmentation reflects how DBS cards enable decentralized sampling, streamlined logistics, and stable biomarker preservation across varied clinical and research workflows. Vendors focus on assay compatibility, pre-analytical quality, and regulatory alignment to expand use-cases from screening to precision medicine. Partnerships with reference labs and diagnostics majors continue to broaden menu offerings, while innovations in coated media and low-volume collection support future growth.
New Born Screening (NBS)
NBS remains a cornerstone use-case as health systems prioritize early detection of inherited metabolic, endocrine, and hematologic disorders. DBS cards are valued for sample integrity, easy transport, and long-term archiving, enabling centralized confirmatory testing from remote birthing centers. Market players emphasize standardized punching, punch carryover mitigation, and quality control rings to ensure reproducibility across high-throughput workflows.
Infectious Diseases Testing
Adoption in infectious disease programs is driven by simplified collection for serology and molecular assays, particularly in outreach and surveillance. DBS reduces cold chain dependencies and improves program reach for screening of HIV, hepatitis, and emerging pathogens. Suppliers highlight validated elution protocols and card chemistries that preserve analytes, supporting reliable downstream PCR and immunoassay performance.
Therapeutic Drug Monitoring
DBS underpins home-based and ambulatory therapeutic drug monitoring by enabling microsampling with less invasive workflows. Clinicians benefit from adherence tracking and frequent sampling without clinic visits, while labs build bioanalytical methods optimized for hematocrit management and recovery. The segment attracts collaborations between pharma, CROs, and specialty labs to qualify assays for real-world drug management.
Forensics
In forensics, DBS cards facilitate secure, chain-of-custody–compliant collection and long-term storage of blood evidence. Their compact format aids evidence transport and archival across jurisdictions, while stabilized spots support DNA analysis and toxicology workflows. Vendors compete on tamper-evident packaging, barcoding, and traceability features that streamline casework.
CRO/Research
CRO and academic research settings leverage DBS to scale cohort studies and remote trial designs with simplified logistics. The format reduces participant burden and enables population-scale biobanking, while method development addresses matrix effects and spot homogeneity. Growth is reinforced by open-access protocols, kit standardization, and integration with ePRO/eCOA platforms in decentralized trials.
Others
This segment spans veterinary testing, toxicology screening, and niche clinical applications where portability and stability are critical. Emerging demand arises from employer wellness programs and telehealth sampling kits that rely on user-friendly collection. Suppliers differentiate through instructional design, error-proofing (e.g., saturation guides), and compatibility with diverse analytical platforms.
Dried Blood Spot Collection Cards Market, Segmentation by Card Type
The Card Type mix reflects trade-offs between cellulose substrates, chemical treatments, and nucleic acid stabilization designed to protect analytes across transport and storage. Buyers evaluate cards on analyte recovery, punch quality, and method transfer across LC-MS/MS, PCR, and immunoassays. Portfolio strategies emphasize IFU clarity, lot-to-lot consistency, and integration with collection accessories such as desiccants and humidity indicators.
Whatman 903
Whatman 903 is widely referenced in NBS and clinical protocols, favored for its validated performance and broad historical adoption. Laboratories value its consistent fiber matrix that supports uniform spot formation and reproducible punching. Ongoing focus areas include method robustness, compliance with global QC schemes, and supply continuity for large screening programs.
Ahlstrom 226
Ahlstrom 226 competes on substrate engineering and manufacturing quality that underpin reliable analyte recovery. Users cite compatible punching and wetting behavior that aid standardized workflows across test menus. Market positioning emphasizes global availability, close collaboration with assay developers, and documentation that supports regulatory submissions.
FTA
FTA cards incorporate chemical treatments that lyse cells and protect nucleic acids against degradation and microbial growth, supporting long-term storage. They are adopted in forensics and molecular epidemiology, where DNA stability and biosafety are critical. Vendors promote validated extraction protocols and compatibility with downstream PCR workflows to ensure consistent yield.
Others
The Others category covers specialized and private-label cards featuring coatings, barrier layers, or humidity control tailored to specific analytes. Buyers assess total cost-in-use including kitting, shipping, and training, not just card price. Innovation focuses on low-volume microsampling, device-card hybrids, and sustainability-minded materials.
Dried Blood Spot Collection Cards Market, Segmentation by End Use
End-user demand is anchored in the operational realities of clinical care and diagnostic testing, with additional pull from research ecosystems. Procurement priorities include traceability, HL7/LIS integration via barcodes, and training support for consistent specimen quality. Strategic growth levers feature decentralized testing models, telehealth workflows, and expansion into resource-limited settings.
Hospitals & Clinics
Hospitals & Clinics adopt DBS for routine screening, specialty diagnostics, and follow-up testing that benefits from easy collection. Integrated supply arrangements and infection control protocols support standardization across departments. Stakeholders emphasize clinical governance, competency training, and compatibility with central labs for confirmatory testing.
Diagnostics Centers
Diagnostics Centers leverage DBS to serve broad catchment areas with courier-friendly workflows and scalable accessioning. The format enables menu expansion into remote geographies while maintaining turnaround time targets. Competitive advantage hinges on method validation, automation readiness, and partnerships with public health programs.
Others
The Others end-use segment includes occupational health, employer wellness, and home collection initiatives that prioritize convenience. Growth aligns with digital engagement, patient-friendly instructions, and robust sample stability through last-mile delivery. Vendors co-develop kits and support materials to minimize pre-analytical variability.
Dried Blood Spot Collection Cards Market, Segmentation by Geography
In this report, Dried Blood Spot Collection Cards Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
North America
North America benefits from established NBS programs, advanced diagnostics infrastructure, and active decentralized trial ecosystems. Procurement emphasizes regulatory compliance, QC participation, and dependable supply for statewide screening. Growth levers include telehealth sampling, expanded infectious disease surveillance, and integration with digital LIMS and barcoding.
Europe
Europe shows strong uptake through coordinated public health frameworks and cross-border research collaborations. Emphasis is placed on data protection, standardized SOPs, and sustainability in packaging and logistics. Market expansion is supported by laboratory networks, pan-European quality schemes, and adoption in molecular screening and TDM initiatives.
Asia Pacific
Asia Pacific exhibits fast-growing demand as health systems scale screening coverage and expand diagnostic access to remote regions. Governments and private providers invest in sample transport and cold-chain alternatives, aligning with DBS strengths. Local manufacturing partnerships and technology transfer support affordability and broader assay availability.
Middle East & Africa
Middle East & Africa reliance on public health programs and donor-funded initiatives encourages DBS adoption for surveillance and screening. Priorities include training, standardized kits, and robust traceability to ensure consistent pre-analytical quality. Partnerships with regional reference laboratories help centralize confirmatory testing and method validation.
Latin America
Latin America leverages DBS to expand access across diverse geographies while containing logistics costs. Health ministries and private labs pursue menu expansion in NBS, infectious disease, and TDM, supported by education for collectors and caregivers. Market momentum is reinforced by procurement consortia, localization of supply, and improved LIS connectivity.
Dried Blood Spot Collection Cards Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Dried Blood Spot Collection Cards Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers:
- Convenience in Sample Collection
- Logistics and Shipping Efficiency
- Minimized Biohazard Risks
-
Increasing Demand for Point-of-Care Testing: The dried blood spot (DBS) collection cards market is experiencing a significant uptick in demand, driven primarily by the increasing adoption of point-of-care testing (POCT) solutions worldwide. POCT offers several advantages, including rapid diagnostic results, reduced turnaround times, and enhanced patient convenience, making it particularly valuable in settings where immediate clinical decisions are crucial. DBS cards play a pivotal role in POCT by simplifying the collection, storage, and transportation of blood samples, thereby facilitating decentralized testing in various healthcare settings.
The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases is further bolstering the demand for POCT solutions using DBS cards. These cards enable healthcare providers to conduct diagnostic tests outside traditional laboratory environments, such as in clinics, emergency rooms, and remote or resource-limited settings. Moreover, advancements in DBS technology, including improved sample stability and analytical sensitivity, are enhancing the reliability and accuracy of POCT results. As healthcare systems globally strive to improve patient outcomes and reduce healthcare costs, the integration of DBS collection cards in POCT workflows is expected to continue expanding, catering to the growing demand for accessible and efficient diagnostic solutions.
Restraints:
- Variability in Sample Quality
- Limited Volume of Blood Collection
- Potential Hematocrit Interference
-
Challenges in Analytical Sensitivity: One of the significant challenges facing the dried blood spot (DBS) collection cards market is maintaining adequate analytical sensitivity in diagnostic and research applications. DBS cards are designed to preserve small volumes of blood samples dried onto filter paper, which can sometimes result in lower analyte concentrations compared to traditional liquid blood samples. This lower concentration can pose challenges for analytical methods that require high sensitivity, such as detecting low-abundance biomarkers or accurately measuring drug levels in therapeutic drug monitoring. Ensuring consistent and reliable results across different analytes and concentrations remains a critical concern for stakeholders in clinical laboratories and research settings using DBS cards.
Factors such as hematocrit levels (the proportion of red blood cells in whole blood) can affect the accuracy and reproducibility of analytical results from DBS samples. Variations in hematocrit levels among individuals can impact the distribution of analytes within DBS samples, leading to potential biases in test outcomes. Addressing these challenges requires ongoing advancements in analytical techniques, assay methodologies, and DBS card technologies to improve sensitivity, precision, and robustness. As the demand for DBS collection cards continues to grow across diverse medical and research applications, overcoming these analytical sensitivity challenges will be crucial for maintaining their relevance and effectiveness in modern diagnostic and healthcare practices.
Opportunities:
- Expansion in Newborn Screening Programs
- Growing Applications in Therapeutic Drug Monitoring
- Increasing Demand in Infectious Disease Screening
-
Adoption in Biomarker Discovery and Validation: The dried blood spot (DBS) collection cards market is increasingly recognized for its pivotal role in biomarker discovery and validation, revolutionizing how researchers and clinicians approach disease diagnosis and treatment monitoring. DBS cards offer a practical solution for collecting and storing blood samples, preserving biomarkers that can be crucial in identifying disease indicators, monitoring treatment efficacy, and predicting patient outcomes. This capability is particularly valuable in personalized medicine, where biomarkers serve as essential tools for tailoring therapies to individual patient profiles.
In biomedical research, DBS cards enable efficient sample collection from large study populations, supporting epidemiological studies, clinical trials, and longitudinal research projects. They facilitate the analysis of biomarkers associated with various diseases such as cancer, cardiovascular disorders, infectious diseases, and metabolic conditions. DBS technology also enhances the feasibility of biomarker studies in resource-limited settings and remote locations, where traditional blood collection and transportation methods may be impractical. As advancements in analytical techniques and biomarker identification continue to evolve, the adoption of DBS collection cards is expected to expand further, driving innovation in precision medicine and accelerating the translation of biomarker discoveries into clinical applications.
Dried Blood Spot Collection Cards Market Competitive Landscape Analysis
Dried Blood Spot Collection Cards Market is characterized by intense competition, with companies leveraging diverse strategies such as partnerships, product diversification, and collaboration to strengthen their market positions. The focus on innovation in sample collection and storage drives competitive advantage, while emerging players aim to capture a significant percentage of the expanding diagnostics sector.
Market Structure and Concentration
The market demonstrates moderate concentration, with leading firms maintaining dominance through strong strategies, technological advancements, and long-term partnerships. Niche manufacturers compete by targeting specialized research and clinical applications. The competitive balance shifts as mergers and collaboration enhance scalability, fostering steady growth and broader market penetration.
Brand and Channel Strategies
Prominent brands focus on targeted strategies to improve distribution, utilizing multi-channel partnerships with laboratories, healthcare providers, and research institutions. Investment in direct-to-lab platforms supports enhanced market presence, while collaboration with diagnostic service providers strengthens accessibility. Differentiation through branding and optimized channel structures sustains long-term growth.
Innovation Drivers and Technological Advancements
Rapid technological advancements in collection card materials, bio-sample preservation, and automation are reshaping the competitive environment. Leading players emphasize innovation in microfluidic technologies and integrated testing methods. Continuous collaboration with diagnostic developers accelerates precision and reliability, enabling manufacturers to expand capabilities and secure a larger percentage of the diagnostics market.
Regional Momentum and Expansion
Geographic expansion strategies dominate, with companies forming partnerships to enhance distribution networks and strengthen presence in emerging markets. Investments in localized manufacturing and collaboration with regional laboratories improve operational efficiency. Regional competitiveness is further influenced by regulatory harmonization and accelerated adoption, driving consistent growth across multiple territories.
Future Outlook
The future of the market emphasizes sustainable growth driven by product innovation, advanced technological advancements, and robust partnerships. With increased integration of automated workflows and expanding clinical applications, leading companies are expected to enhance efficiency and scalability. Strategic collaboration and adaptive business models will remain critical in shaping the market’s competitive trajectory.
Key players in Dried Blood Spot Collection Cards Market include:
- QIAGEN
- Roche
- PerkinElmer, Inc.
- Shimadzu Corporation
- Ahlstrom-Munksjo Oyj
- Pall Corporation
- Eastern Business Forms, Inc.
- Archimed Life Science GmbH
- CENTOGENE N.V.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific
- Agilent Technologies
- Whatman
- MilliporeSigma
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Application Type
- Market Snapshot, By Card Type
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Dried Blood Spot Collection Cards Market Forces
- Drivers, Restraints and Opportunities
- Drivers
-
Convenience in Sample Collection
-
Logistics and Shipping Efficiency
-
Minimized Biohazard Risks
-
Increasing Demand for Point-of-Care Testing
-
- Restraints
-
Variability in Sample Quality
-
Limited Volume of Blood Collection
-
Potential Hematocrit Interference
-
Challenges in Analytical Sensitivity
-
- Opportunities
-
Expansion in Newborn Screening Programs
-
Growing Applications in Therapeutic Drug Monitoring
-
Increasing Demand in Infectious Disease Screening
-
Adoption in Biomarker Discovery and Validation
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Dried Blood Spot Collection Cards Market, By Application Type, 2021 - 2031 (USD Million)
- New Born Screening (NBS)
- Infectious Diseases Testing
- Therapeutic Drug Monitoring
- Forensics
- CRO/Research
- Others
- Dried Blood Spot Collection Cards Market, By Card Type, 2021 - 2031 (USD Million)
- Whatman 903
- Ahlstrom 226
- FTA
- Others
- Dried Blood Spot Collection Cards Market, By End Use, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Diagnostics Centers
- Others
- Dried Blood Spot Collection Cards Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Dried Blood Spot Collection Cards Market, By Application Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- QIAGEN
- Roche
- PerkinElmer, Inc.
- Shimadzu Corporation
- Ahlstrom-Munksjo Oyj
- Pall Corporation
- Eastern Business Forms, Inc.
- Archimed Life Science GmbH
- CENTOGENE N.V.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific
- Agilent Technologies
- Whatman
- MilliporeSigma
- Company Profiles
- Analyst Views
- Future Outlook of the Market

